GORE® VIABAHN®
Endoprosthesis
with Heparin Bioactive Surface*



PREDICTABLE PERFORMANCE WITH ENHANCEMENTS IN ACCESS AND DELIVERY

Large diameter configurations with lower delivery profile

- Expanded accessibility through smaller sheaths.
- Smaller sheath sizes result in a lower risk of vascular access complications in select patient populations.[1]

Endoprosthesis labeled diameter (mm)†	Recommended vessel diameter (mm)‡	Legacy profile (Fr)	New lower profile (Fr)
9	7.6–8.5	◯ 9	◯ 8
10	8.6–9.5	◯ 11	◯ 8
11	9.6–10.5	◯ 11	◯ 10
13	10.6–12.0	◯ 12	◯ 10§

- Enhanced visualization under fluoroscopy
  - Four gold radiopaque markers on the distal and proximal ends for more confident delivery in complex cases



* As used by Gore, Heparin Bioactive Surface refers to Gore's proprietary CBAS Heparin Surface.
† Labeled device diameters and lengths are nominal.
‡ Recommended endoprosthesis compression within the vessel is approximately 5–20%.
§ The 13 mm diameter device is not compatible with the 10 Fr COOK FLEXOR CHECK-FLO Introducer.

Together, improving life

Continued innovation for durable outcomes and unmatched versatility

- Proven patency*
- Demonstrated durability*
- Fewer reinterventions*
- Broadly indicated*

1996
Original GORE® HEMOBAHN® Endoprosthesis introduced in Europe

2002
Original device introduced in U.S. as GORE® VIABAHN® Endoprosthesis

2003
TIP to HUB deployment introduced on 6–8 mm devices

2005
6–8 mm devices in U.S. receive FDA approval for SFA indication



2007
GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface introduced in U.S.

5–8 mm devices decreased in profile by one French size

2008
All device sizes receive FDA approval for Iliac artery indication

2009
Laser technology enables the new contoured edge at proximal end

9–13 mm devices introduced with 0.035" guidewire compatibility

2011
GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface 5–8 mm devices decreased in profile by one French size

2013
FDA approval for Revision of Arteriovenous Access Grafts

25 cm Length: Longest stent graft introduced in U.S.

2014
5–7 mm devices receive FDA approval for treatment of in-stent restenosis in the SFA

Radiopaque markers on endoprosthesis introduced on 5–8 mm devices

2016
7.5 cm length introduced in U.S. for 5–9 mm devices

2020
Up to 3 Fr size reduction in profile and addition of radiopaque markers on 9–13 mm devices

* GORE® VIABAHN® Endoprosthesis. W. L. Gore & Associates website. Accessed July 29, 2020. https://www.goremedical.com/VIABAHN/references.

Reference

1. Applegate RJ, Sacrinty MT, Kutcher MA, et al. Trends in vascular complications after diagnostic cardiac catheterization and percutaneous coronary intervention via the femoral artery, 1998 to 2007. *JACC: Cardiovascular Interventions* 2008;1(3):317-326.

Consult Instructions for Use
eifu.goremedical.com

INTENDED USE/INDICATIONS: The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery de novo and restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 7.5 mm. The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery in-stent restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 6.5 mm. The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in iliac artery lesions up to 80 mm in length with reference vessel diameters ranging from 4.0 – 12 mm. The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface is also indicated for the treatment of stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous (AV) access grafts. **CONTRAINDICATIONS:** The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface is contraindicated for non-compliant lesions where full expansion of an angioplasty balloon catheter was not achieved during pre-dilatation, or where lesions cannot be dilated sufficiently to allow passage of the delivery system. Do not use the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface in patients with known hypersensitivity to heparin, including those patients who have had a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II. Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. ℞ Only

Products listed may not be available in all markets.

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 67332882 **Australia/New Zealand** 1800 680 424 **Europe** 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771